[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"neuralgia-postherpetic\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:neuralgia-postherpetic":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,55,81],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":13,"conditions":26,"keywords":30,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":54},"100647919","phase-3-extended-release-pregabalin-for-the-treatment-of-neuropathic-pain-in-patients-with-diabetic-peripheral-neuropathy-and-postherpetic-neuralgia-100647919",false,"NCT07712913","Extended-release Pregabalin for the Treatment of Neuropathic Pain in Patients With Diabetic Peripheral Neuropathy and Postherpetic Neuralgia","A Phase III, Multicenter, Randomized, Double-blind, Double-dummy, Controlled, Parallel-group, Non-inferiority Clinical Trial to Evaluate the Efficacy and Safety of Extended-release Pregabalin Tablets Compared With Immediate-release Pregabalin Tablets, in the Relief of Neuropathic Pain in Participants With Diabetic Peripheral Neuropathy or Postherpetic Neuralgia.","PRISE","Inclusion Criteria:\n\nThe following criteria must be met for a participant to be included in the study:\n\n1. Participants of either sex, aged 18 to 75 years.\n2. Be able to understand and agree to participate in the study, undergo the procedures, and attend the visits, as indicated by signing the informed consent form approved by the CEP\u002FConep System.\n3. Have a diagnosis of peripheral neuropathic pain associated with:\n\n   * diabetes mellitus (type 1 or 2), with glycated hemoglobin (HbA1c) levels ≤ 11%, documented symptoms of peripheral diabetic neuropathy for at least 6 months, and use of medication for glycemic control at a stable dose for at least 30 days.\n   * postherpetic neuralgia, with pain symptoms for at least 3 months following a skin rash due to an acute episode of herpes zoster.\n4. Presence of neuropathic pain, with an intensity of ≥ 4 on the 11-point DPRS numerical scale (from 0 \"no pain\" to 10 \"worst possible pain\"‡). ‡ Pain intensity ≥ 4 will be confirmed at the initial visit (IV); during the screening\u002Frandomization visit, Participant Diary No. 1 containing the DPRS scales will be provided, in which the participant will record pain intensity daily upon waking and at the end of the day for 7 days (±2 days). The mean value for pain intensity recorded during the Screening\u002FRandomization Phase will be used to confirm eligibility at the initial visit (IV).\n5. Participants who are unable to become pregnant (postmenopausal women, defined as 12 months or more of amenorrhea, or who have undergone surgical sterilization\\*; and men who have undergone vasectomy\\*\\*) OR participants of reproductive potential who agree to use a reliable method of contraception\\*\\*\\*.\n\n   * Female sterilization (undergoing bilateral surgical oophorectomy with or without hysterectomy), total hysterectomy, or tubal ligation at least 6 weeks prior to administration of the investigational drug.\n\n     * Male sterilization at least 6 months prior to screening. \\*\\*\\* If the participant is of childbearing age and decides to participate in the study, they must use or request that their partner use a safe contraceptive method. A safe contraceptive method is defined as the use of at least one of the following: condoms, a diaphragm, and\u002For a hormonal method (estrogenic and\u002For progestogenic) in the form of medication, including oral, vaginal, injectable, transdermal, and intrauterine devices. Only participants who expressly declare themselves exempt from the risk of pregnancy-whether because they do not engage in sexual activity or because they engage in it in a non-reproductive manner-will have the right to participate in the study without the mandatory use of contraceptives. Examples include participants who have undergone a vasectomy, those with an infertile partner, or those practicing total heterosexual abstinence.\n\nThe decision regarding the best contraceptive method to use will be made jointly by the physician and the study participant. If there are any costs involved, the chosen contraceptive method will be provided by the sponsor free of charge for as long as necessary. In addition, condoms with spermicide will be provided to participants at all study visits, when applicable.\n\nExclusion Criteria:\n\nA positive response to any of the following criteria will exclude the participant from the study:\n\n1. The presence of pain unrelated to the primary diagnosis of diabetic peripheral neuropathy or postherpetic neuralgia that could interfere with the evaluation.\n2. Any skin condition that potentially alters sensation in the affected dermatome or area of neuropathic involvement, which could interfere with the assessment.\n3. Having undergone neurosurgical therapy for the treatment of neuropathy.\n4. Current use, or use within the past 7 days, of nerve block therapy and\u002For medications commonly used to treat neuropathic pain (e.g., benzodiazepines, skeletal muscle relaxants, capsaicin, local anesthetics, opioids, memantine), antiepileptic drugs (e.g., carbamazepine, clonazepam, phenytoin, valproic acid, lamotrigine, topiramate, gabapentin), antidepressants (e.g., tricyclics, serotonin reuptake inhibitors, venlafaxine), and potential neurotoxins (e.g., hydroxychloroquine, deferoxamine, thioridazine, vigabatrin).\n5. History of treatment failure or hypersensitivity to pregabalin or gabapentin.\n6. History of neoplastic disease within the past 2 years (excluding basal cell carcinoma), neurological disease, unstable heart disease, psychiatric conditions (particularly suicidal ideation), and\u002For infection with hepatitis B, hepatitis C, or HIV.\n7. Current laboratory abnormalities in liver enzymes (elevated AST and\u002For ALT 2.5 times the upper limit of the reference range) and\u002For renal insufficiency (glomerular filtration rate \\\u003C 60 mL\u002Fmin\u002F1.73 m²).\n8. History of illicit drug abuse in the past 2 years.\n9. History of alcoholism (average alcohol intake exceeding 3 standard drinks\\* per day or more than 7 standard drinks per week for women, and exceeding 4 standard drinks per day or more than 14 standard drinks per week for men) in the past 2 years.\n\n   \\* A standard drink is: a can of regular beer (330 mL at 4%); a shot of distilled spirits (30 mL at 40%); a glass of wine or a small glass of sherry (100 mL at 12% or 70 mL at 18%); a small glass of liqueur or similar (50 mL at 25%) (53).\n10. Being pregnant, breastfeeding, or intending to become pregnant during the study period.\n11. Having participated in clinical studies in the past 12 (twelve) months, unless there may be a direct benefit to the study participant, at the investigator's discretion.\n12. Having any condition that prevents participation, at the investigator's discretion.","ALL","18 Years","75 Years",{"count":21,"type":22},348,"ESTIMATED","INTERVENTIONAL",[25],"PHASE3",[27,28,29],"Diabetic Neuropathy","Neuropathic Pain","Neuralgia, Postherpetic",[31,32,33,34,35,36,37,38,39,40,41],"multicenter","randomized","double-blind","double-dummy","controlled","parallel-group","non-inferiority","diabetic","postherpetic neuralgia","peripheral neuropathy","Pregabalin","RECRUITING","2026-07-13",{"date":45,"type":46},"2026-07-20","ACTUAL",{"date":48,"type":46},"2026-06-18",{"date":50,"type":22},"2027-06-01",{"name":52,"class":53},"Brainfarma Industria Química e Farmacêutica S\u002FA","INDUSTRY",15,{"id":56,"slug":57,"hasResults":11,"nctId":58,"briefTitle":59,"officialTitle":59,"acronym":4,"eligibilityCriteria":60,"healthyVolunteers":11,"sex":17,"minAge":61,"maxAge":62,"enrollmentInfo":63,"targetDuration":4,"studyType":23,"phases":65,"briefSummary":67,"conditions":68,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":80},"100589802","phase-4-high-voltage-long-duration-pulsed-radiofrequency-combined-with-liposomal-bupivacaine-subcutaneous-block-for-herpes-zoster-associated-neuralgia-100589802","NCT06959147","High-Voltage Long-Duration Pulsed Radiofrequency Combined With Liposomal Bupivacaine Subcutaneous Block for Herpes Zoster-Associated Neuralgia","Inclusion Criteria:\n\nPatients diagnosed with zoster-associated neuralgia (ZAN) who meet ALL of the following conditions:\n\n* Voluntarily provided written informed consent.\n* Inadequate response to pharmacological or other non-surgical therapies OR intolerable drug-related adverse effects.\n* Herpes zoster (HZ) lesions involving cranial\u002Fcervicocephalic, cervical, thoracic, or lumbar dermatomes.\n* Moderate-to-severe pain intensity, defined as a Numerical Rating Scale (NRS) score ≥4 at baseline.\n* Aged between 40 and 85 years.\n* Body weight: Male ≥50 kg; female ≥45 kg.\n\nExclusion Criteria:\n\n* Severe cardiovascular diseases or life-threatening arrhythmias (e.g., heart failure, third-degree atrioventricular block without pacemaker implantation).\n* Contraindications to minimally invasive interventions (e.g., coagulation disorders, active infections).\n* Allergy to local anesthetics or lipid emulsions; Severe dysfunction of vital organs (cardiac, pulmonary, hepatic, or renal) rendering the patient unfit for the procedure.\n* Severe endocrine disorders or long-term use of corticosteroids\u002Fimmunosuppressive agents.\n* Cognitive impairment or inability to cooperate with treatment protocols.\n* Prior history of neuromodulation therapies (e.g., spinal cord stimulation or pulsed radiofrequency (PRF) treatment).","40 Years","85 Years",{"count":64,"type":22},46,[66],"PHASE4","Research Objectives Background and Significance: Zoster-associated neuralgia (ZAN) refers to neuropathic pain experienced by herpes zoster (HZ) patients before, during, and after rash resolution, characterized by paroxysmal, lightning-like, or knife-like sensations. Postherpetic neuralgia (PHN), a common type of chronic pain, is often accompanied by physical-psychological impairments, social dysfunction, and anxiety-depression. While high-voltage long-term pulsed radiofrequency (HL-PRF) has become a conventional treatment for ZAN, it is limited by residual postoperative localized pain and suboptimal efficacy for refractory cases. Liposomal bupivacaine (LB), a sustained-release analgesic providing up to 72 hours of pain relief, offers potential for combined subcutaneous injection to enhance symptomatic control.\n\nStudy Process:\n\nThis clinical study focuses on evaluating the efficacy of HL-PRF combined with LB subcutaneous injection in treating ZAN. The trial will be conducted from December 16, 2024, to December 14, 2026, with an anticipated enrollment of 92 participants. Patients will be randomized into two groups:\n\nHL-PRF group: Under CT-guided localization, high-voltage pulsed radiofrequency (HL-PRF) therapy was precisely delivered to the pathologically compromised dorsal root ganglion (DRG).\n\nHL-PRF+LB group: HL-PRF treatment followed by LB subcutaneous injection at the painful lesion site 2 hours post-procedure.\n\nClinical data will be collected preoperatively, and inflammatory factors will be assessed on the first postoperative day. Follow-up evaluations via telephone will occur at 1 week, 1 month, 3 months, and 6 months postoperatively. By analyzing changes in observed indicators before and after treatment, this study aims to determine the clinical efficacy of combining HL-PRF with LB subcutaneous injection for ZAN.",[69,29],"Herpes Zoster Pain","2025-04-27",{"date":72,"type":46},"2025-05-06",{"date":74,"type":46},"2024-12-17",{"date":76,"type":22},"2026-05-31",{"name":78,"class":79},"Shirong Tan","OTHER",1,{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":87,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":89,"targetDuration":4,"studyType":23,"phases":91,"briefSummary":93,"conditions":94,"keywords":96,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":80},"100583914","subcutaneous-lidocaine-injection-in-acute-herpes-zoster-neuralgia-and-post-herpetic-neuralgia-100583914","NCT06882525","Subcutaneous Lidocaine Injection in Acute Herpes Zoster Neuralgia and Post-herpetic Neuralgia","The Evaluation of the Effectiveness of Subcutaneous Lidocaine Injection in Acute Herpes Zoster Neuralgia and Post-herpetic Neuralgia","SCL-HZ\u002FPHN","Inclusion Criteria:\n\n* patients over the age of 18\n* with acute HZ pain (rash duration \\\u003C 30 days\n* pain due to PHN (rash duration \\> 3 months),\n\nExclusion Criteria:\n\npatients on anticoagulants or have coagulation disorders, patients with psychomotor disorders patients with uncontrolled diabetes patients with bacterial infection or infectious discharge in the affected dermatomal region patients allergic to lidocaine patients with lesions in the facial or genital regions pregnant or breastfeeding patients",{"count":90,"type":22},76,[92],"NA","In this study, it was aimed to compare the effect of subcutaneous lidocaine injection, which is routinely applied in pain clinic,in patients who present with pain complaints due to acute herpes zoster and post-herpetic neuralgia, and investigate its contribution to preventing the development of post-herpetic neuralgia",[95,29],"Herpes Zoster",[29,97,98],"HERPES ZOSTER","Lidocaine","NOT_YET_RECRUITING","2025-03-17",{"date":102,"type":46},"2025-03-18",{"date":104,"type":22},"2025-03-07",{"date":106,"type":22},"2025-12-06",{"name":108,"class":79},"Ankara City Hospital Bilkent"]